454678-91-2

Usage

Uses

Used in Organic Synthesis:
4-(1,3-Thiazol-2-yl)benzyl alcohol is utilized as a building block in organic synthesis for its ability to facilitate the creation of complex organic molecules. Its structural features make it a versatile component in the synthesis of a wide array of compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4-(1,3-Thiazol-2-yl)benzyl alcohol is employed as a key intermediate in the development of new drugs. Its antimicrobial and antifungal properties are particularly valuable for the creation of medications targeting various infections.
Used in Fragrance and Flavor Production:
4-(1,3-Thiazol-2-yl)benzyl alcohol is used as a raw material in the production of fragrances and flavors due to its aromatic properties. Its distinctive scent and taste make it a valuable addition to the formulations of various consumer products in the fragrance and flavor industries.
Overall, 4-(1,3-Thiazol-2-yl)benzyl alcohol's diverse applications across different industries highlight its importance as a multifunctional chemical compound with significant potential for further research and development.

InChI:InChI=1/C10H9NOS/c12-7-8-1-3-9(4-2-8)10-11-5-6-13-10/h1-6,12H,7H2

Upstream product

• 198904-53-9 4-(thiazol-2-yl)-benzaldehyde 
• 130534-91-7 1-bromo-4-[(methoxymethyloxy)methyl]benzene 
• 873-75-6 4-bromobenzenemethanol 
• 454678-92-3 4-[(methoxymethyloxy)methyl]-phenylboric acid 
• 3034-53-5 2-bromo-1,3-thiazole 
• 59016-93-2 p-hydroxymethylphenylboronic acid 
• 454678-93-4 2-{4-[(methoxymethyloxy)methyl]phenyl}thiazole 

Downstream Products

• 1083364-05-9 C₁₀H₈FNOS 
• 1187451-26-8 4-(thiazol-2-yl)benzyl bromide 
• 1187450-47-0 tert-butyl [tert-butoxycarbonyl(6-{(pyridin-3-ylsulfonyl)[4-(thiazol-2-yl)benzyl]-aminomethyl}pyridin-2-yl)amino]acetate 
• 1187451-27-9 2-{4-[bis(tert-butoxycarbonyl)aminomethyl]phenyl}thiazole 
• 1187450-46-9 (6-{(pyridin-3-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}-pyridin-2-ylamino)acetic acid 
• 1187450-50-5 (6-{(pyridin-3-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}pyridin-2-ylamino)acetic acid hydrochloride 
• 1187450-75-4 (6-{(pyridin-3-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}pyridin-2-ylamino)-acetic acid trifluoroacetate 
• 1273387-05-5 N,N-dimethyl-2-(6-{(pyridin-2-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}pyridin-2-ylamino)acetamide 
• 1273387-06-6 2-{2-[2-(benzyloxy)ethoxy]ethoxy}ethyl 2-({6-[(N-{[4-(1,3-thiazol-2-yl)phenyl]methyl}pyridine-2-sulfonamido)methyl]pyridin-2-yl}amino)acetate 
• 1273387-07-7 {2-[2-(2-hydroxyethoxy)ethoxy]ethyl} (6-{(pyridin-2-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}pyridin-2-ylamino)acetate 
• 1273387-09-9 pivaloyloxymethyl (6-{(pyridin-2-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}pyridin-2-ylamino)acetate 
• 1273387-11-3 [2-(morpholin-4-yl)ethyl] (6-{(pyridin-2-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}pyridin-2-ylamino)acetate 
• 1273387-13-5 docosyl (6-{(pyridin-2-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}pyridin-2-yl-amino)acetate 
• 906352-61-2 2[4-(chloromethyl)phenyl]-1,3-thiazole 

Relevant academic research and scientific papers

Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility

Following the approval of delamanid and pretomanid as new drugs to treat drug-resistant tuberculosis, there is now a renewed interest in bicyclic nitroimidazole scaffolds as a source of therapeutics against infectious diseases. We recently described a nitroimidazopyrazinone bicyclic subclass with promising antitubercular and antiparasitic activity, prompting additional efforts to generate analogs with improved solubility and enhanced potency. The key pendant aryl substituent was modified by (i) introducing polar functionality to the methylene linker, (ii) replacing the terminal phenyl group with less lipophilic heterocycles, or (iii) generating extended biaryl side chains. Improved antitubercular and antitrypanosomal activity was observed with the biaryl side chains, with most analogs achieved 2- to 175-fold higher activity than the monoaryl parent compounds, with encouraging improvements in solubility when pyridyl groups were incorporated. This study has contributed to understanding the existing structure-activity relationship (SAR) of the nitroimidazopyrazinone scaffold against a panel of disease-causing organisms to support future lead optimization.

REDUCTION OF PRO-INFLAMMATORY HDL USING A LEUKOTRIENE INHIBITOR

A method involving the administration of a therapeutically effective amount of a leukotriene inhibitor, a pharmaceutically acceptable salt, a pharmaceutically acceptable N-oxide, a pharmaceutically active metabolite, a pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof to a human for reducing a level of pro-inflammatory HDL in the human. Various examples of leukotriene inhibitors, including 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin- 3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2, 2-dimethyl-propionic acid, are disclosed for administration for the reduction of pro-inflammatory HDL in a human. Reduction of pro-inflammatory HDL by the leukotriene inhibitor may include conversion of at least a portion of pro-inflammatory HDL to anti-inflammatory HDL.

PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA

The present invention is to provide a medical composition for the treatment or prophylaxis of glaucoma which comprises a pyridylaminoacetic acid compound represented by the formula (1): wherein R1, R2 and R3 each independe

SUBSTITUTED CARBONYL COMPOUNDS

This is to provide a novel substituted carbonyl compound represented by the following formula (I) having an excellent bronchodilatory action based on potent EP2 agonistic action and useful for treatment of respiratory diseases. A compound represented by t

PYRIDYLAMINOACETIC ACID COMPOUND

The present invention provides a novel pyridylaminoacetic acid compound represented by the following formula (1): (wherein R1, R2, R3, Y and Z are as defined in the description and claims), or a pharmacologically acceptabl

5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS

Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF

The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein one of Q and T represents a group represented by the general formula: while the other represents a lower alkyl group or a halo(lower alkyl) gr